Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing revealed previously undetected mutations in RAS/BRAF (71%) and EGFR (47%), which often emerged polyclonally.
|
31350822 |
2019 |
Progressive Neoplastic Disease
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We report 2 patients with BRAF V600 mutant melanoma who were previously treated with anti-PD-1±anti-LAG-3 antibodies and were switched to BRAF/MEK-inhibitors because of progressive disease.
|
29939877 |
2019 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease.
|
29624648 |
2018 |
Progressive Neoplastic Disease
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this retrospective multicenter study with 60 patients suffering from inoperable or metastatic melanoma we evaluated the efficacy of re-challenge with a BRAF inhibitor (BRAF2) with or without MEK-inhibition after progressive disease upon previous treatment with a BRAF inhibitor (BRAF1) with or without MEK inhibition.
|
30344946 |
2018 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG.
|
28727518 |
2017 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
|
27105424 |
2016 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025).
|
26857243 |
2016 |
Progressive Neoplastic Disease
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Despite major advancements in targeted therapy of metastatic melanoma, most patients relapse and show progressive disease after 5-7 months with single inhibition of BRAF or MEK.
|
25602684 |
2015 |
Progressive Neoplastic Disease
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease might continue to respond to BRAF inhibition.
|
25980594 |
2015 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition, leading mostly to incomplete responses that may favor the selection of a sub-population of resistant clones and the acquisition of alterations that cause tumor regrowth and progressive disease.
|
25344914 |
2014 |
Progressive Neoplastic Disease
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although no melanomas had high-level amplification of BRAF, the two patients with progressive disease as their best response had BRAF copy gain in their tumors.
|
23833299 |
2013 |
Progressive Neoplastic Disease
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |